Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × temsirolimus × 90 days × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Sarcoma 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 PRETEXT I Hepatoblastoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Desmoplastic Small Round Cell Tumor 1 Carcinoma, Renal Cell 1 Brain Neoplasms 1 Advanced Cancer 1 Adult Solid Neoplasm 1

Interventions

pembrolizumab 27 Nivolumab 26 cabozantinib 25 Magnetic Resonance Spectroscopy 19 Specimen Handling 16 Ipilimumab 16 lenvatinib 10 belzutifan 7 atezolizumab 7 Biopsy 7 Axitinib 7 Sunitinib 6 Everolimus 6 CTLA-4 Antigen 6 avelumab 5 aldesleukin 5 Radiosurgery 5 Immunoglobulin G 5 Bevacizumab 5 pazopanib 4 fludarabine 4 Disulfides 4 Cyclophosphamide 4 zimberelimab 3 palbociclib 3 cemiplimab 3 Radiotherapy 3 Nephrectomy 3 IFL protocol 3 toripalimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02184416 2026-02-27

ADONIS

Pfizer

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡